Kamada has been granted an Orphan Drug Designation by the FDA for its Alpha-1 Antitrypsin (AAT) product to treat type 1 diabetes. The company is currently undergoing a Phase I/II clinical trial with AAT by IV route of administration.
Kamada plans to publish an interim and/or the final reports during 2012.
David Tsur, Chief Executive Officer of Kamada said: "We are excited to enter the diabetes field and hope to bring a global breakthrough in the treatment of juvenile diabetes and potential cure."
To learn more about orphan drugs, check out the World Orphan Drug Congress USA.